CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Net product sales	$ 249,172	$ 5,468	$ 576,622	$ 14,934
Sanofi collaboration revenue	145,042	79,802	319,035	249,577
Bayer HealthCare collaboration revenue	26,701	10,094	48,308	33,698
Technology licensing	5,893	5,893	17,679	18,966
Contract research and other	879	1,576	2,231	5,672
Total revenues	427,687	102,833	963,875	322,847
Expenses:
Research and development	158,295	127,924	444,530	400,465
Selling, general, and administrative	46,883	32,916	153,016	80,912
Cost of goods sold	20,145	450	54,286	1,227
Total expenses	225,323	161,290	651,832	482,604
Income (loss) from operations	202,364	(58,457)	312,043	(159,757)
Other income (expense):
Investment income	517	715	1,628	2,750
Interest expense	(11,413)	(4,061)	(33,809)	(11,827)
Total other income (expense)	(10,896)	(3,346)	(32,181)	(9,077)
Income (loss) before income taxes	191,468	(61,803)	279,862	(168,834)
Income tax (expense) benefit		(562)		517
Net income (loss)	191,468	(62,365)	279,862	(168,317)
Net income (loss) per share - basic	$ 2.02	$ (0.68)	$ 2.97	$ (1.87)
Net income (loss) per share - diluted	$ 1.72	$ (0.68)	$ 2.55	$ (1.87)
Weighted average shares outstanding - basic	95,012	91,046	94,349	90,215
Weighted average shares outstanding - diluted	115,830	91,046	109,780	90,215
Condensed Statements of Comprehensive Income (Loss)
Net income (loss)	191,468	(62,365)	279,862	(168,317)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax	467	(827)	(42)	760
Comprehensive income (loss)	$ 191,935	$ (63,192)	$ 279,820	$ (167,557)